Yan Shao1,2,3,4, Manqiao Wang1,2,3,4, Yimeng Zhu1,2,3,4, Xiaorong Li5,6,7,8, Juping Liu9,10,11,12. 1. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin, China. 2. Tianjin Branch of National Clinical Research Center for Ocular Disease, Tianjin, China. 3. Eye Institute and School of Optometry, Tianjin, China. 4. Tianjin Medical University Eye Hospital, Tianjin, China. 5. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin, China. xiaorli@163.com. 6. Tianjin Branch of National Clinical Research Center for Ocular Disease, Tianjin, China. xiaorli@163.com. 7. Eye Institute and School of Optometry, Tianjin, China. xiaorli@163.com. 8. Tianjin Medical University Eye Hospital, Tianjin, China. xiaorli@163.com. 9. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin, China. tydljp@126.com. 10. Tianjin Branch of National Clinical Research Center for Ocular Disease, Tianjin, China. tydljp@126.com. 11. Eye Institute and School of Optometry, Tianjin, China. tydljp@126.com. 12. Tianjin Medical University Eye Hospital, Tianjin, China. tydljp@126.com.
Abstract
PURPOSE: To investigate the effect of metformin combined with anti-VEGF agents in patients with diabetic macular edema (DME). METHODS: This study was a prospective, nonrandomized case-control study. Patients were included in with a diagnosis of DME who received anti-VEGF agents injection. Basic information, medical history, best-corrected visual acuity (BCVA), central macular thickness (CMT), the number of intravitreal injections, panretinal photocoagulation (PRP), and macular grid photocoagulation treatment during the 6-month follow-up, were recorded for each patient. RESULTS: A total of 50 DME patients were collected (24 patients with a history of oral metformin ≥ 6 months and 26 patients who had not taken metformin). The BCVA and the CMT were significantly improved after anti-VEGF treatment in two groups (F1 = 19.35, F2 = 26.78; F1 = 65.45, F2 = 76.23; P < 0.05). The BCVA in the metformin group was better than that in non-metformin group at every point after treatment (F = 34.45, P < 0.05). The CMT in metformin group decreased much more than that in non-metformin group during the follow-up period (F = 87.05, P < 0.05). The injection numbers decreased in the metformin group compared with the non-metformin group (t = 5.14, P < 0.05). However, there was no difference in PRP and macular grid photocoagulation therapy between the two groups during the 6-month follow-up. CONCLUSION: Metformin can enhance the therapeutic effect of anti-VEGF agents on DME patients to improve their visual acuity, improve the structure of the macular area, and reduce the number of intravitreal injections 90.
PURPOSE: To investigate the effect of metformin combined with anti-VEGF agents in patients with diabetic macular edema (DME). METHODS: This study was a prospective, nonrandomized case-control study. Patients were included in with a diagnosis of DME who received anti-VEGF agents injection. Basic information, medical history, best-corrected visual acuity (BCVA), central macular thickness (CMT), the number of intravitreal injections, panretinal photocoagulation (PRP), and macular grid photocoagulation treatment during the 6-month follow-up, were recorded for each patient. RESULTS: A total of 50 DME patients were collected (24 patients with a history of oral metformin ≥ 6 months and 26 patients who had not taken metformin). The BCVA and the CMT were significantly improved after anti-VEGF treatment in two groups (F1 = 19.35, F2 = 26.78; F1 = 65.45, F2 = 76.23; P < 0.05). The BCVA in the metformin group was better than that in non-metformin group at every point after treatment (F = 34.45, P < 0.05). The CMT in metformin group decreased much more than that in non-metformin group during the follow-up period (F = 87.05, P < 0.05). The injection numbers decreased in the metformin group compared with the non-metformin group (t = 5.14, P < 0.05). However, there was no difference in PRP and macular grid photocoagulation therapy between the two groups during the 6-month follow-up. CONCLUSION: Metformin can enhance the therapeutic effect of anti-VEGF agents on DME patients to improve their visual acuity, improve the structure of the macular area, and reduce the number of intravitreal injections 90.
Authors: Jocelyn T Chin; Joshua J Troke; Naoyuki Kimura; Satoshi Itoh; Xi Wang; Owen P Palmer; Robert C Robbins; Michael P Fischbein Journal: Yale J Biol Med Date: 2011-12